Maui Hypothetical? The funds are not raised and that was

New Post Public Reply Private Reply Replies (3) Message Board
acraft5 Mauibound #8783
510
Maui

Hypothetical? The funds are not raised and that was confirmed by Rory in the CEO Report update. Are you listening to them? It's at the ~38 min mark. The Capital Raise was delayed due to the Audit of SC. The audit was just recently finalized and I GUARANTEE that we don't have the 20M raised yet. Venture Capitalists don't put up money without audited financials....EVER.

Yes, they do seem integrated but what if the investment community isn't ready to support them at this time. You do realize as an investor that it's not a slam dunk don't you?

While nFusz is listed under the SuiteApp page they are hardly integrated. Again Rory stated they there were issues with V2 so Oracle has not issued a PR and they had to rewrite it to work with NS. Still waiting on V3.

I am an investor just like you but I chose to ask hard questions instead of have my pom poms out with blinders on. I want to discuss the real issues nFusz is facing and not be attacked by you because you have set your sites on Maui without looking at the hardline of a startup company. It just shows how naive you really are.

Think about this. Many investors bought in from $2-3. This is now at .21. If they do a 1-40 RS that means it would go to ~$10/share. If you had 40k shares at an average of 2.50/share and now you have 1k shares at ~10/share after the RS it has to get to $100/share just to break even. How long do you think that will be before they recoup their investment? And that's not to say it won't drop after the RS which it may for a while. So while some of you are poking fun at "losers" for selling you need to rethink your position on that and have a little compassion for them instead of saying they are weak or lacking of vision.

I love what I see but there are real hurdles that have to be navigated and there have been many missed goals in the past year. A 1-40 RS will be a disaster if announced. They have to get the price up organically with real market acceptance before they continue with the uplist in my opinion. If they don't then they either can't or don't care about the investors that have been with them for the last 2 years.

Like I have said before I like Rory and I think he genuinely cares about stock holders. I just think he gets too excited as a CEO and says things are coming when they are farther off than he thinks. And that lack of a PR from Oracle is still haunting this stock. He kept saying it was coming on multiple occasions and we still don't have one from them. In fact he stated recently that they now have a new connection at Oracle which means they pretty much wrote us off at one point.

Good Luck to all of us.
5

TON Strategy Co. (TONX) Stock Research Links

TONX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Celebrating Excellence: The 2025 Audio Description Awards Gala

Updated Category News Views 181

Join the Celebration at the 2025 Audio Description Awards Gala The American Council of the Blind (ACB) warmly invites everyone to participate in the highly anticipated 5th Annual Audio Description Awards Gala. Set to take place in November 2025, this event promises to be a dazzling showcase of talent, creativity, and inclusivity within the media landscape. With a focus on...

Continue Reading
The Alkaline Water Company Expands Its Reach in the Midwest

Updated Category News Views 177

The Alkaline Water Company's Growth in the Midwest Market The Alkaline Water Company, Inc. (OTC: WTER), a prominent name in the beverage industry, is making waves with its latest expansion efforts. With a focus on providing high-quality purified alkaline water enhanced with Himalayan rock salt, the company has recently partnered with Pete's Market, a well-respected...

Continue Reading
SELLAS Life Sciences Doses First Pediatric AML Patient in Trial

Updated Category News Views 177

SELLAS Life Sciences Takes a Major Step in Pediatric AML Treatment SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) has reached a significant milestone by dosing the first pediatric patient in their ongoing Phase 2 trial of SLS009, a groundbreaking treatment aimed at relapsed/refractory acute myeloid leukemia (r/r AML). This development marks a notable advancement in their...

Continue Reading
Almara Women's Health Revolutionizes Care for Women Everywhere

Updated Category News Views 407

Almara Women's Health Launches Innovative Whole-Woman Care Uniting Seven Twin Cities Practices Under One Vision Almara Women's Health is introducing a groundbreaking model of care specifically designed for women of all ages. This newly unified collaboration of healthcare providers is set to transform the way women experience healthcare, ensuring that all aspects of their...

Continue Reading
Exploring the Growing Influence of Marketing Platforms Today

Updated Category News Views 115

The Surge of Influencer Marketing Platforms The global influencer marketing platform market is on a significant upward trajectory. This dynamic industry is projected to expand from USD 10.6 billion in 2023 to USD 14.2 billion in just one year, ultimately reaching a colossal USD 50.3 billion by 2028. Such extraordinary growth indicates a CAGR of 37.1% from 2024 to 2028....

Continue Reading